RTTNews | Jun 22, 2021 09:18AM EDT

09:18 Tuesday, June 22, 2021 (RTTNews.com) - Corcept Therapeutics Inc. (CORT) said that preliminary results from its phase 3 RELIANT trial of relacorilant combined with nab-paclitaxel in patients with metastatic pancreatic cancer suggested that the combination of the therapy is active in patients, but the apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer. Therefore the company has stopped patient enrollments in the trial.

In Tuesday pre-market trade, CORT was trading at $20.30 down $2.68 or 11.66 percent.

Two of 31 evaluable patients exhibited tumor shrinkage designated as a partial response, a response rate of six percent, while 15 patients achieved stable disease for at least 12 weeks. The combination was well-tolerated. These data are similar to those of phase 1 study, the company said in a statement.

The company noted that its development program in solid tumors continues to advance. It plans to initiate a pivotal trial for that indication in the first quarter of 2022. It is based on the positive results of controlled Phase 2 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.

The company stated that its trials of relacorilant plus pembrolizumab in patients with adrenal cancer and of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer continue to enroll.

The company is evaluating relacorilant as a potential treatment for patients with earlier stages of pancreatic cancer and with other glucocorticoid receptor-expressing tumors.

Read the original article on RTTNews ( https://www.rttnews.com/3204067/corcept-s-relacorilant-fails-to-show-substantial-benefit-in-metastatic-pancreatic-cancer-trial.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved